<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03902392</url>
  </required_header>
  <id_info>
    <org_study_id>5480</org_study_id>
    <nct_id>NCT03902392</nct_id>
  </id_info>
  <brief_title>Red Grape Polyphenol Oral Administration to Women Affected by Nickel-mediated Allergic Contact Dermatitis</brief_title>
  <acronym>Grapolyphen</acronym>
  <official_title>Oral Human Administration of Red Grape Polyphenol in Nickel-mediated Allergic Contact Dermatitis: an in Vitro Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Bari</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Bari</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Nickel (Ni)-mediated allergic contact dermatitis (ACD) is a very common disease worldwide.
      Our previous findings demonstrated that in vitro supplementation of polyphenols, extracted
      from seeds of red grape (Nero di Troia cultivar), to peripheral lymphomonocytes from
      Ni-mediated ACD patients could reduce release of T helper (h)1 [interferon (IFN)-] and Th2
      [interleukin (IL)-4] cytokines, on the one hand. On the other hand, IL-10 (an
      anti-inflammatory cytokine) levels increased with a reduction of IL-17 (an inflammatory
      cytokine). Also levels of nitric oxide (NO) decreased in response to polyphenol pretreatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nickel (Ni) is a transitional metal largely distributed in the environment whose continuous
      exposure is able to provoke local and systemic allergic contact dermatitis (ACD). Ni-mediated
      ACD is characterized by loss of epidermal integrity, urticaria/angioedema, flares, and
      itching, whose extent depends on many variables such as genetic, time of sensitization and
      environmental exposure.The aim of the present research is to verify whether the oral
      administration of polyphenols (NATUR-OX®) to patients with Ni-mediated ACD is able to modify
      immune parameters.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 16, 2018</start_date>
  <completion_date type="Actual">October 31, 2018</completion_date>
  <primary_completion_date type="Actual">September 10, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of Serum Biomarker Concentrations at the Time of Enrollment (T0)</measure>
    <time_frame>Baseline (T0)</time_frame>
    <description>At the time of enrollment (T0) concentrations of serum biomarkers (pg/ml) (IFN-γ, IL-17, IL-4, IL-10, PTX3 and NO) will be evaluated in patients of which, one group (A) will assume polyphenols (NATUR-OX ) while the other group (B) will assume placebo. Of note, from each group 7 spontaneously dropouts occurred. An ELISA method will be use to analyze and to assess serum biomarker concentrations.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Serum Biomarker Concentrations at the End of the Treatment (T1)</measure>
    <time_frame>After 3 months (T1)</time_frame>
    <description>Serum biomarkers (IFN-γ, IL-17, IL-4, IL-10, PTX3 and NO) (pg/ml) in the same patients of both groups A and B whose received for 3 months Polyphenols (NATUR-OX) and placebo, respectively, were evaluated. To analyze serum biomarkers an ELISA method were used .</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Allergic Contact Dermatitis</condition>
  <arm_group>
    <arm_group_label>NATUR-OX Group (A)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administration, for three months (T1), of NATUR-OX® capsule/day. NATUR-OX® which is a dietary supplement containing grape seed extracts from Nero di Troia (Vitis vinifera). Each capsule contains 280 mg of proanthocyanidins where Ni contamination of capsule is below 0.24 ppm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group (B)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administration with placebo one capsule/daily for three months. The placebo capsules had the same appearance and composition of the supplement except for the active ingredient (polyphenols)</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>NaturOx Group (A)</intervention_name>
    <description>Comparison between dietary supplement and placebo</description>
    <arm_group_label>NATUR-OX Group (A)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Group (B)</intervention_name>
    <description>Comparison between dietary supplement and placebo</description>
    <arm_group_label>Placebo Group (B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patient; Age: 25-60 Years; Ni-mediated ACD (positive reaction to the nickel
             patch test)

        Exclusion Criteria:

          -  Absence of other pathologies such as immune-mediated diseases, metabolic diseases
             (diabetes and obesity)

          -  infectious episodes in the last month and intake of immunosuppressive drugs or drugs
             influencing the immune response.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Caterina CF Foti, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Bari</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thea Magrone</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Magrone T, Romita P, Verni P, Salvatore R, Spagnoletta A, Magrone M, Russo MA, Jirillo E, Foti C. In vitro Effects of Polyphenols on the Peripheral Immune Responses in Nickel-sensitized Patients. Endocr Metab Immune Disord Drug Targets. 2017 Nov 16;17(4):324-331. doi: 10.2174/1871530317666171003161314.</citation>
    <PMID>28982342</PMID>
  </results_reference>
  <results_reference>
    <citation>Johansen JD, Aalto-Korte K, Agner T, Andersen KE, Bircher A, Bruze M, Cannavó A, Giménez-Arnau A, Gonçalo M, Goossens A, John SM, Lidén C, Lindberg M, Mahler V, Matura M, Rustemeyer T, Serup J, Spiewak R, Thyssen JP, Vigan M, White IR, Wilkinson M, Uter W. European Society of Contact Dermatitis guideline for diagnostic patch testing - recommendations on best practice. Contact Dermatitis. 2015 Oct;73(4):195-221. doi: 10.1111/cod.12432. Epub 2015 Jul 14.</citation>
    <PMID>26179009</PMID>
  </results_reference>
  <results_reference>
    <citation>Summer B, Ständer S, Thomas P. Cytokine patterns in vitro, in particular IL-5/IL-8 ratio, to detect patients with nickel contact allergy. J Eur Acad Dermatol Venereol. 2018 Sep;32(9):1542-1548. doi: 10.1111/jdv.14931. Epub 2018 Mar 26.</citation>
    <PMID>29524267</PMID>
  </results_reference>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>February 14, 2019</study_first_submitted>
  <study_first_submitted_qc>April 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2019</study_first_posted>
  <results_first_submitted>April 11, 2019</results_first_submitted>
  <results_first_submitted_qc>December 10, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">January 2, 2020</results_first_posted>
  <last_update_submitted>December 10, 2019</last_update_submitted>
  <last_update_submitted_qc>December 10, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">January 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Bari</investigator_affiliation>
    <investigator_full_name>Thea Magrone</investigator_full_name>
    <investigator_title>Aggregate Professor of Immunology</investigator_title>
  </responsible_party>
  <keyword>Allergic contact dermatitis</keyword>
  <keyword>Cytokines</keyword>
  <keyword>Cellular and molecular rehabilitation</keyword>
  <keyword>Immune response</keyword>
  <keyword>Nickel</keyword>
  <keyword>Polyphenols</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Contact</mesh_term>
    <mesh_term>Dermatitis, Allergic Contact</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 31, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/92/NCT03902392/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 31, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/92/NCT03902392/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>NATUR-OX Group (A)</title>
          <description>Administration, for three months (T1), of NATUR-OX® capsule/day. NATUR-OX® which is a dietary supplement containing grape seed extracts from Nero di Troia (Vitis vinifera). Each capsule contains 280 mg of proanthocyanidins where Ni contamination of capsule is below 0.24 ppm
NaturOx Group (A): Comparison between dietary supplement and placebo</description>
        </group>
        <group group_id="P2">
          <title>Placebo Group (B)</title>
          <description>Administration with placebo one capsule/daily for three months. The placebo capsules had the same appearance and composition of the supplement except for the active ingredient (polyphenols)
Placebo Group (B): Comparison between dietary supplement and placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>7 dropouts for each group.</population>
      <group_list>
        <group group_id="B1">
          <title>NATUR-OX Group (A)</title>
          <description>Administration, for three months (T1), of NATUR-OX® capsule/day. NATUR-OX® which is a dietary supplement containing grape seed extracts from Nero di Troia (Vitis vinifera). Each capsule contains 280 mg of proanthocyanidins where Ni contamination of capsule is below 0.24 ppm
NaturOx Group (A): Comparison between dietary supplement and placebo</description>
        </group>
        <group group_id="B2">
          <title>Placebo Group (B)</title>
          <description>Administration with placebo one capsule/daily for three months. The placebo capsules had the same appearance and composition of the supplement except for the active ingredient (polyphenols)
Placebo Group (B): Comparison between dietary supplement and placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="18"/>
            <count group_id="B3" value="36"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Eighteen patients received NATUR-OX (age range 28-59). Eighteen patients received placebo (age range 25-60).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.7" lower_limit="28" upper_limit="59"/>
                    <measurement group_id="B2" value="42.5" lower_limit="25" upper_limit="60"/>
                    <measurement group_id="B3" value="42.5" lower_limit="25" upper_limit="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Number of patients enrolled who are Italian.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Evaluation of IFN-γ at T0</title>
          <description>Twenty-five patients were enrolled, and they were administered with polyphenols (NATUR-OX (A), instead other 25 patients were enrolled to assume placebo (B). From each group 7 dropouts occurred.</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.53" spread="3.85"/>
                    <measurement group_id="B2" value="16.03" spread="3.521"/>
                    <measurement group_id="B3" value="15.28" spread="3.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Evaluation of IL-17 at T0</title>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97.58" spread="5.576"/>
                    <measurement group_id="B2" value="95.34" spread="3.982"/>
                    <measurement group_id="B3" value="96.46" spread="4.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Evaluation of IL-4 at T0</title>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="109.1" spread="8.944"/>
                    <measurement group_id="B2" value="110.7" spread="8.805"/>
                    <measurement group_id="B3" value="109.87" spread="8.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Evaluation of IL-10 at T0</title>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14.19" spread="3.494"/>
                    <measurement group_id="B2" value="15.86" spread="3.847"/>
                    <measurement group_id="B3" value="15.03" spread="3.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Evaluation of PTX3 at T0</title>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="410.7" spread="46.34"/>
                    <measurement group_id="B2" value="415.6" spread="52.73"/>
                    <measurement group_id="B3" value="413.11" spread="48.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Evaluation of No concentrations at T0</title>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.401" spread="1.140"/>
                    <measurement group_id="B2" value="2.380" spread="1.233"/>
                    <measurement group_id="B3" value="2.39" spread="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Evaluation of Serum Biomarker Concentrations at the Time of Enrollment (T0)</title>
        <description>At the time of enrollment (T0) concentrations of serum biomarkers (pg/ml) (IFN-γ, IL-17, IL-4, IL-10, PTX3 and NO) will be evaluated in patients of which, one group (A) will assume polyphenols (NATUR-OX ) while the other group (B) will assume placebo. Of note, from each group 7 spontaneously dropouts occurred. An ELISA method will be use to analyze and to assess serum biomarker concentrations.</description>
        <time_frame>Baseline (T0)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NATUR-OX Group (A)</title>
            <description>Administration, for three months (T1), of NATUR-OX® capsule/day. NATUR-OX® which is a dietary supplement containing grape seed extracts from Nero di Troia (Vitis vinifera). Each capsule contains 280 mg of proanthocyanidins where Ni contamination of capsule is below 0.24 ppm
NaturOx Group (A): Comparison between dietary supplement and placebo</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group (B)</title>
            <description>Administration with placebo one capsule/daily for three months. The placebo capsules had the same appearance and composition of the supplement except for the active ingredient (polyphenols)
Placebo Group (B): Comparison between dietary supplement and placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Serum Biomarker Concentrations at the Time of Enrollment (T0)</title>
          <description>At the time of enrollment (T0) concentrations of serum biomarkers (pg/ml) (IFN-γ, IL-17, IL-4, IL-10, PTX3 and NO) will be evaluated in patients of which, one group (A) will assume polyphenols (NATUR-OX ) while the other group (B) will assume placebo. Of note, from each group 7 spontaneously dropouts occurred. An ELISA method will be use to analyze and to assess serum biomarker concentrations.</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IFN-γ (measurement unit: pg/ml)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.53" spread="3.85"/>
                    <measurement group_id="O2" value="16.03" spread="3.521"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-4 (measurement unit: pg/ml)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109.1" spread="8.944"/>
                    <measurement group_id="O2" value="110.7" spread="8.805"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-17(measurement unit: pg/ml)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.58" spread="5.576"/>
                    <measurement group_id="O2" value="95.34" spread="3.982"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-10 (measurement unit: pg/ml)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.19" spread="3.494"/>
                    <measurement group_id="O2" value="15.86" spread="3.847"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTX3 (measurement unit: pg/ml)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="410.7" spread="46.34"/>
                    <measurement group_id="O2" value="415.6" spread="52.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NO concentration (measurement unit: pg/ml)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.401" spread="1.140"/>
                    <measurement group_id="O2" value="2.380" spread="1.233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluation of Serum Biomarker Concentrations at the End of the Treatment (T1)</title>
        <description>Serum biomarkers (IFN-γ, IL-17, IL-4, IL-10, PTX3 and NO) (pg/ml) in the same patients of both groups A and B whose received for 3 months Polyphenols (NATUR-OX) and placebo, respectively, were evaluated. To analyze serum biomarkers an ELISA method were used .</description>
        <time_frame>After 3 months (T1)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NATUR-OX Group (A)</title>
            <description>Administration, for three months (T1), of NATUR-OX® capsule/day. NATUR-OX® which is a dietary supplement containing grape seed extracts from Nero di Troia (Vitis vinifera). Each capsule contains 280 mg of proanthocyanidins where Ni contamination of capsule is below 0.24 ppm
NaturOx Group (A): Comparison between dietary supplement and placebo</description>
          </group>
          <group group_id="O2">
            <title>Placebo Group (B)</title>
            <description>Administration with placebo one capsule/daily for three months. The placebo capsules had the same appearance and composition of the supplement except for the active ingredient (polyphenols)
Placebo Group (B): Comparison between dietary supplement and placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluation of Serum Biomarker Concentrations at the End of the Treatment (T1)</title>
          <description>Serum biomarkers (IFN-γ, IL-17, IL-4, IL-10, PTX3 and NO) (pg/ml) in the same patients of both groups A and B whose received for 3 months Polyphenols (NATUR-OX) and placebo, respectively, were evaluated. To analyze serum biomarkers an ELISA method were used .</description>
          <units>pg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>IFN-γ (measurement unit: pg/ml)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.41" spread="3.964"/>
                    <measurement group_id="O2" value="17.29" spread="3.687"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-4 (measurement unit: pg/ml)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.57" spread="8.770"/>
                    <measurement group_id="O2" value="112.2" spread="8.840"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-17 (measurement unit: pg/ml)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.36" spread="5.374"/>
                    <measurement group_id="O2" value="100.6" spread="4.519"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IL-10 (measurement unit: pg/ml)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.67" spread="5.586"/>
                    <measurement group_id="O2" value="11.19" spread="2.737"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PTX3 (measurement unit: pg/ml)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="365.3" spread="46.08"/>
                    <measurement group_id="O2" value="455.9" spread="50.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NO concentration (measurement unit: pg/ml)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.381" spread="0.7823"/>
                    <measurement group_id="O2" value="2.619" spread="1.262"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>NATUR-OX Group (A)</title>
          <description>Administration, for three months (T1), of NATUR-OX® capsule/day. NATUR-OX® which is a dietary supplement containing grape seed extracts from Nero di Troia (Vitis vinifera). Each capsule contains 280 mg of proanthocyanidins where Ni contamination of capsule is below 0.24 ppm
NaturOx Group (A): Comparison between dietary supplement and placebo</description>
        </group>
        <group group_id="E2">
          <title>Placebo Group (B)</title>
          <description>Administration with placebo one capsule/daily for three months. The placebo capsules had the same appearance and composition of the supplement except for the active ingredient (polyphenols)
Placebo Group (B): Comparison between dietary supplement and placebo</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Thea TM Magrone, BD</name_or_title>
      <organization>University of Bari</organization>
      <phone>+39 080 5478584</phone>
      <email>thea.magrone@uniba.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

